SEQENS

SEQENS Overview

SEQENS is a global leader in pharmaceutical solutions and specialty ingredients. They provide a range of products, including generic and custom APIs, intermediates, and excipients for pharmaceuticals, along with ingredients for personal care and specialty chemicals. With 16 production sites and 9 R&D centers across 9 countries, SEQENS serves over 1,500 customers in more than 80 countries. In 2021, Private equity group SK Capital Partners has completed the acquisition of a majority stake in French firm Seqens, at the same time merging portfolio company Wavelength Pharmaceuticals into Seqens.

Latest News

Dec 21, 2021 · www.chemanager-online.com

growth-positive

SK Capital Creates new CDMO from Seqens and Wavelength | CHEManager

Seqens has emerged stronger following a merger, now operating 24 industrial sites and 10 R&D centers globally. The company plans to accelerate ongoing projects and strengthen its global customer support. SK Capital, Bpifrance, and Nov Santé have invested in Seqens, with historical shareholders Mérieux Equity Partners, Ardian, and Eximium reinvesting. Seqens has also sold its non-core mineral specialties activities, which will remain under the control of former shareholder Eurazeo and other historical shareholders. Eurazeo announced discussions to sell its stake in Seqens to SK Capital, with the deal expected to close by the end of 2021.

InvestmentAcquired-by

Team Members

1

Employees: 11-50

Web & Social Links

Locations

Be'er Sheva, Israel

France

Photos & Videos

No files yet

SEQENS Internal

Recent Updates

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info